Literature DB >> 18292803

Curcumin prevents and reverses murine cardiac hypertrophy.

Hong-Liang Li1, Chen Liu, Geoffrey de Couto, Maral Ouzounian, Mei Sun, Ai-Bing Wang, Yue Huang, Cheng-Wei He, Yu Shi, Xin Chen, Mai P Nghiem, Youan Liu, Manyin Chen, Fayez Dawood, Masahiro Fukuoka, Yuichiro Maekawa, Liyong Zhang, Andrew Leask, Asish K Ghosh, Lorrie A Kirshenbaum, Peter P Liu.   

Abstract

Chromatin remodeling, particularly histone acetylation, plays a critical role in the progression of pathological cardiac hypertrophy and heart failure. We hypothesized that curcumin, a natural polyphenolic compound abundant in the spice turmeric and a known suppressor of histone acetylation, would suppress cardiac hypertrophy through the disruption of p300 histone acetyltransferase-dependent (p300-HAT-dependent) transcriptional activation. We tested this hypothesis using primary cultured rat cardiac myocytes and fibroblasts as well as two well-established mouse models of cardiac hypertrophy. Curcumin blocked phenylephrin-induced (PE-induced) cardiac hypertrophy in vitro in a dose-dependent manner. Furthermore, curcumin both prevented and reversed mouse cardiac hypertrophy induced by aortic banding (AB) and PE infusion, as assessed by heart weight/BW and lung weight/BW ratios, echocardiographic parameters, and gene expression of hypertrophic markers. Further investigation demonstrated that curcumin abrogated histone acetylation, GATA4 acetylation, and DNA-binding activity through blocking p300-HAT activity. Curcumin also blocked AB-induced inflammation and fibrosis through disrupting p300-HAT-dependent signaling pathways. Our results indicate that curcumin has the potential to protect against cardiac hypertrophy, inflammation, and fibrosis through suppression of p300-HAT activity and downstream GATA4, NF-kappaB, and TGF-beta-Smad signaling pathways.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18292803      PMCID: PMC2248327          DOI: 10.1172/JCI32865

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  45 in total

Review 1.  Recent advances in cardiac development with therapeutic implications for adult cardiovascular disease.

Authors:  Jonathan A Epstein; Michael S Parmacek
Journal:  Circulation       Date:  2005-07-26       Impact factor: 29.690

2.  Epigallocathechin-3 gallate inhibits cardiac hypertrophy through blocking reactive oxidative species-dependent and -independent signal pathways.

Authors:  Hong-Liang Li; Yue Huang; Chan-Na Zhang; Guang Liu; Yu-Sheng Wei; Abi-Bing Wang; Yu-Qing Liu; Rui-Tai Hui; Chiming Wei; G Metville Williams; De-Pei Liu; Chih-Chuan Liang
Journal:  Free Radic Biol Med       Date:  2006-05-15       Impact factor: 7.376

3.  Long-term activation of adenosine monophosphate-activated protein kinase attenuates pressure-overload-induced cardiac hypertrophy.

Authors:  Hong-Liang Li; Ran Yin; Dandan Chen; Dan Liu; Dong Wang; Qinglin Yang; Yu-Gang Dong
Journal:  J Cell Biochem       Date:  2007-04-01       Impact factor: 4.429

4.  Isorhapontigenin, a new resveratrol analog, attenuates cardiac hypertrophy via blocking signaling transduction pathways.

Authors:  Hong-Liang Li; Ai-Bing Wang; Yue Huang; De-Pei Liu; Chiming Wei; G Metville Williams; Chan-Na Zhang; Guang Liu; Yu-Qing Liu; De-Long Hao; Rui-Tai Hui; Mao Lin; Chih-Chuan Liang
Journal:  Free Radic Biol Med       Date:  2005-01-15       Impact factor: 7.376

5.  Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state.

Authors:  Mei Sun; Manyin Chen; Fayez Dawood; Urszula Zurawska; Jeff Y Li; Thomas Parker; Zamaneh Kassiri; Lorrie A Kirshenbaum; Malcolm Arnold; Rama Khokha; Peter P Liu
Journal:  Circulation       Date:  2007-03-12       Impact factor: 29.690

6.  Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity.

Authors:  Chinmay M Trivedi; Yang Luo; Zhan Yin; Maozhen Zhang; Wenting Zhu; Tao Wang; Thomas Floss; Martin Goettlicher; Patricia Ruiz Noppinger; Wolfgang Wurst; Victor A Ferrari; Charles S Abrams; Peter J Gruber; Jonathan A Epstein
Journal:  Nat Med       Date:  2007-02-18       Impact factor: 53.440

7.  IkappaB kinase alpha-mediated derepression of SMRT potentiates acetylation of RelA/p65 by p300.

Authors:  Jamie E Hoberg; Anita E Popko; Catherine S Ramsey; Marty W Mayo
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

8.  Adenosine inhibits collagen and protein synthesis in cardiac fibroblasts: role of A2B receptors.

Authors:  R K Dubey; D G Gillespie; E K Jackson
Journal:  Hypertension       Date:  1998-04       Impact factor: 10.190

9.  Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.

Authors:  Hyun Kook; John J Lepore; Aaron D Gitler; Min Min Lu; Wendy Wing-Man Yung; Joel Mackay; Rong Zhou; Victor Ferrari; Peter Gruber; Jonathan A Epstein
Journal:  J Clin Invest       Date:  2003-09       Impact factor: 14.808

10.  Molecular characterization of angiotensin II--induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype.

Authors:  J Sadoshima; S Izumo
Journal:  Circ Res       Date:  1993-09       Impact factor: 17.367

View more
  39 in total

Review 1.  From genetics to epigenetics: new insights into keloid scarring.

Authors:  Yongjing He; Zhenjun Deng; Mansour Alghamdi; Lechun Lu; Mark W Fear; Li He
Journal:  Cell Prolif       Date:  2017-01-05       Impact factor: 6.831

2.  The virtue of just enough stress: a molecular model.

Authors:  Nanette H Bishopric
Journal:  Trans Am Clin Climatol Assoc       Date:  2012

Review 3.  Epigenetic alterations in acute kidney injury.

Authors:  Karol Bomsztyk; Oleg Denisenko
Journal:  Semin Nephrol       Date:  2013-07       Impact factor: 5.299

Review 4.  Cancer chemoprevention by dietary polyphenols: promising role for epigenetics.

Authors:  Alexander Link; Francesc Balaguer; Ajay Goel
Journal:  Biochem Pharmacol       Date:  2010-06-26       Impact factor: 5.858

Review 5.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 6.  Potential therapeutic effects of curcumin, the anti-inflammatory agent, against neurodegenerative, cardiovascular, pulmonary, metabolic, autoimmune and neoplastic diseases.

Authors:  Bharat B Aggarwal; Kuzhuvelil B Harikumar
Journal:  Int J Biochem Cell Biol       Date:  2008-07-09       Impact factor: 5.085

7.  Cyclin-dependent kinase-9 is a component of the p300/GATA4 complex required for phenylephrine-induced hypertrophy in cardiomyocytes.

Authors:  Yoichi Sunagawa; Tatsuya Morimoto; Tomohide Takaya; Shinji Kaichi; Hiromichi Wada; Teruhisa Kawamura; Masatoshi Fujita; Akira Shimatsu; Toru Kita; Koji Hasegawa
Journal:  J Biol Chem       Date:  2010-01-17       Impact factor: 5.157

8.  Currying favor for the heart.

Authors:  Jonathan A Epstein
Journal:  J Clin Invest       Date:  2008-03       Impact factor: 14.808

9.  Quantitative control of adaptive cardiac hypertrophy by acetyltransferase p300.

Authors:  Jian Qin Wei; Lina A Shehadeh; James M Mitrani; Monica Pessanha; Tatiana I Slepak; Keith A Webster; Nanette H Bishopric
Journal:  Circulation       Date:  2008-08-12       Impact factor: 29.690

10.  Lysosomal cysteine peptidase cathepsin L protects against cardiac hypertrophy through blocking AKT/GSK3beta signaling.

Authors:  Qizhu Tang; Jun Cai; Difei Shen; Zhouyan Bian; Ling Yan; You-Xin Wang; Jie Lan; Guo-Qing Zhuang; Wen-Zhan Ma; Wei Wang
Journal:  J Mol Med (Berl)       Date:  2008-12-19       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.